Delving into the Latest Updates on Human umbilical cord mesenchymal stem cells(Jiangsu Topcel-KH Pharmaceutical) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

MSCs(Jiangsu Topcel-KH Pharmaceutical), Mesenchymal Stem Cells(Jiangsu Topcel-KH Pharmaceutical), Solizmestrocel

+ [1]

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Other DiseasesDigestive System DisordersImmune System Diseases

Active Indication

Crohn DiseasePerianal fistula due to Crohn's diseaseRadiation proctitis+ [1]

Inactive Indication-

Originator Organization

Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.

Active Organization

Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

BACKGROUNDRegenerative medicine researches have shown that mesenchymal stem cells (MSCs) may be an effective treatment method for premature ovarian insufficiency (POI). However, the efficacy of MSCs is still limited.PURPOSEThis study aims to explain whether salidroside and MSCs combination is a therapeutic strategy to POI and to explore salidroside-enhanced MSCs inhibiting ferroptosis via Keap1/Nrf2/GPX4 signaling.METHODSThe effect of salidroside and MSCs on ovarian granular cells (GCs) was analyzed. After treatment, hormone levels and -fertility of rats were measured. Lipid peroxidation levels, iron deposition and mitochondrial morphology were detected. The genes and proteins of Keap1/Nrf2/GPX4 signaling were examined.RESULTSSalidroside and MSCs were found to inhibit cell death of GCs by reducing peroxidation and intracellular ferrous. Salidroside promotes the proliferation of MSCs and supports cell survival in ovary. Salidroside combined with MSCs therapy restored ovarian function, which was better than MSCs monotherapy. Salidroside-enhanced MSCs to inhibit ferroptosis. The results showed activation of the Keap1/Nrf2/GPX4 signaling and an increase in anti-ferroptosis molecule.CONCLUSIONSSalidroside-enhanced MSCs as a ferroptosis inhibitor and provide new therapeutic strategies for POI. The possible mechanisms of MSCs were related to maintaining redox homeostasis via a Keap1/Nrf2/GPX4 signaling.

01 Dec 2025·Current Pain and Headache Reports

A Systematic Review of Regenerative Medicine Therapies for Axial Spine Pain of Facet Joint Origin

Review

Author: Shekoohi, Sahar ; Kaye, Alan D ; Sanapati, Mahendra R ; Pampati, Vidyasagar ; Hirsch, Joshua A ; Abd-Elsayed, Alaa ; Manchikanti, Laxmaiah

PURPOSE OF REVIEWThis review aims to assess the effectiveness of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) injections in treating axial spinal pain originating from the facet joints. A systematic evaluation of available evidence on these biological therapies was conducted to determine their clinical utility.RECENT FINDINGSRecent studies emphasize the therapeutic promise of intraarticular biologics, including MSCs, PRP, and alpha-2-macroglobulin, in managing facet joint-related axial spinal pain. Emerging evidence suggests improvements in pain relief, physical function, and quality of life following these treatments. Based on our search criteria, 20 publications were identified and considered for inclusion. Of these, 4 randomized controlled trials (RCTs) and 6 observational studies met the inclusion criteria. Among the RCTs, 3 trials involved lumbar facet joints, and one trial involved cervical facet joints using PRP. Among the observational studies, 4 studies used PRP, with 3 focusing on the lumbar spine and one study, with 2 publications, on the cervical spine, and only 2 studies evaluated stem cell treatments. The summary of evidence utilizing various criteria, including Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) evidence synthesis, the evidence for PRP injections in facet joints is Level II, or moderate, and Level IV, or limited, overall, with low certainty. For PRP, the recommendation is moderate, and for MSCs, the recommendation is weak.

01 Dec 2025·Current Pain and Headache Reports

A Systematic Review of Sacroiliac Joint Injections of Platelet-Rich Plasma (Prp) and Stem Cells

Review

Author: Hirsch, Joshua A ; Pampati, Vidyasagar ; Sanapati, Mahendra R ; Abd-Elsayed, Alaa ; Manchikanti, Laxmaiah ; Shekoohi, Sahar ; Kaye, Alan D

PURPOSE OF REVIEWThis review evaluates the effectiveness of sacroiliac joint injections of platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) for treating low back and lower extremity pain. A systematic analysis was conducted to assess the impact of PRP and MSC injections on managing these conditions.RECENT FINDINGSIn recent years, several cell-based therapies, including the injection of MSCs and PRP into the sacroiliac joints, have been proposed for the management of low back pain. Emerging clinical evidence supporting their use appears promising. The present systematic review identified 2 randomized controlled trials (RCTs) and 3 observational studies that met inclusion criteria based on strict methodological quality and bias assessments. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework and qualitative analysis synthesis determined evidence levels as IV (limited) with a weak recommendation.

1

News (Medical) associated with Human umbilical cord mesenchymal stem cells(Jiangsu Topcel-KH Pharmaceutical)

13 Mar 2025

·www.prnewswire.com

Infinite Health Integrative Medicine Center Fights Chronic Pain with Stem Cell Prolotherapy

LAKE CHARLES, La., March 13, 2025 /PRNewswire/ -- Infinite Health Integrative Medicine Center, led by Trip Goolsby, MD, is tackling chronic musculoskeletal pain with prolotherapy using mesenchymal signaling cells (MSCs), more popularly known as stem cells. A 2024 study in Stem Cells Translational Medicine (Vol. 13, Issue 10) supports this, showing MSCs repair tissue and reduce inflammation in osteoarthritis and tendon injuries—results Infinite Health sees firsthand. Continue Reading Trip Goolsby, MD Unlike drugs, prolotherapy with MSCs injects stem cells into damaged areas to trigger regeneration, enhanced by Dr. Goolsby's proprietary bio-individualized multi-pillar health optimization program. "Pain does not have to be tolerated and high-risk surgery is not the only option – in fact, surgery should be the last resort," said Dr. Goolsby. "Stem cells spark the body's ability to repair itself naturally. We're proving what science knows." Patients start with comprehensive labs and imaging, then a single MSC session. A 60-year-old walked freely 10 weeks later; a 47-year-old halved Achilles pain in 8. The study aligns: MSCs outperform placebo in function and relief. Costs range from $1,500-$5,000, based on damage and lifestyle. With 50 million Americans in chronic pain (CDC) Infinite Health Integrative Medicine Center leads with results. See for more information and to schedule a $99 introductory consultation via telehealth. Contact: LeNae Goolsby [email protected] | 504-323-0025 SOURCE Infinite Health Integrative Medicine Center WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Human umbilical cord mesenchymal stem cells(Jiangsu Topcel-KH Pharmaceutical)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Crohn Disease	Phase 3	China	Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.	20 Mar 2025
Perianal fistula due to Crohn's disease	Phase 3	China	Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.	20 Jan 2025
Radiation proctitis	Phase 2	China	Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.	24 May 2024
Radiation-induced Rectal Injury	Phase 1	China	Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.	21 Sep 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ECCO2016	Not Applicable	Crohn Disease	48	Standard anti-inflammatory therapy with 5-aminosalicylic acid (5-ASA), glucocorticosteroids (GCS), and immunosuppressive (IS)+MSCs	iypwmgkkhx(wfwtgkguwy) = tzjszmnorp fitcobrzee (tutrhtgmgj ) View more	Positive	12 Feb 2016
				Therapy anti-cytokine ADA	iypwmgkkhx(wfwtgkguwy) = pqprmxcwuj fitcobrzee (tutrhtgmgj ) View more